New pill taken every other day could prevent migraines
NCT ID NCT06409832
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is testing whether the drug rimegepant, taken as a tablet every other day, can help prevent migraines in adults who have at least four migraine days per month. Researchers will track changes in migraine frequency over three to twelve months. The goal is to see if rimegepant is effective and well-tolerated for long-term use.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Rimegepant 75 mg orally disintegrating tablet
What this could lead to
If it works, this could provide a new, well-tolerated option for preventing migraines in people who have frequent attacks.
What could go wrong
This is an early-stage observational study with only 100 participants, so results may not apply to everyone. Rimegepant may not reduce migraine days for all users, and side effects are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MIGRAINE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
IRCCS National Neurological Institute "C. Mondino" Foundation
RECRUITINGPavia, Pavia, 27100, Italy
Contact Email: •••••@•••••
-
SOD Centro Cefalee e Farmacologia Clinica, AOU Careggi
RECRUITINGFlorence, Florence, 50134, Italy
Contact Email: •••••@•••••